ClinicalTrials.gg
RecruitingNCT07710131Updated Nov 20, 2026

Neurocognitive Assessment CNSL and LGG

An interventional study of Digital Cognitive Assessment (TestMyBrain and Mobile Toolbox) and Traditional Neuropsychological Testing in PCNSL, Brain Tumor and Cognitive Dysfunction, sponsored by Dana-Farber Cancer Institute. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by Dana-Farber Cancer Institute · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Started Sep 2026; still recruiting 2 months later.
Updated Nov 20, 2026Now RecruitingFirst site in United States+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
36
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 15 studies in Brain Neoplasms by Dana-Farber Cancer Institute — 4 open to participants now, 7 under way, none of them phase 3. Brain Neoplasms · Dana-Farber Cancer Institute.

Planned enrollment
8th of 12
36 · median 43
Started
2026
the only one that year
No phase
4 of 15
4 open now
Registered
14th of 15
by date

Among the 15 studies in Brain Neoplasms by Dana-Farber Cancer Institute, this one is the 8th largest by planned enrollment of the 12 interventional ones that give a count, is the only one that started in 2026, is one of 4 with no phase, and was the 14th registered.

Brain Neoplasms

2,447 studies on the registry are indexed under Brain Neoplasms; 546 are open to participants now.

Browse Brain Neoplasms studies →

Open to participants now

4 of the 15 studies in Brain Neoplasms by Dana-Farber Cancer Institute are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 429 Brain Neoplasms studies recruiting now, 289 (67%) set no upper age limit and 83 (19%) stop at 75 or younger; 80 take children under 18; 37 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Brain Neoplasms by Dana-Farber Cancer Institute, or all of them as a file.
02

Study summary

This study is to determine whether self-administered digital cognitive tests can serve as accurate and reliable alternatives to established neuropsychological tests for evaluating cognitive functioning in participants with primary central nervous system lymphoma and low-grade gliomas.

Read the detailed description

This is a prospective, longitudinal, pilot study evaluating the validity and reliability of select digital cognitive tests compared to traditional neuropsychological measures in participants with newly diagnosed primary central nervous system lymphoma (PCNSL) and IDH-mutant low-grade gliomas (LGG).

Participants will complete both traditional paper-and-pencil neuropsychological tests and digital cognitive assessments at baseline, 6 months, and at post-treatment or 12-month follow-up, depending on diagnosis. Quality of life and mood will be assessed using the FACT-br and HADS questionnaires and Brain MRI (Magnetic Resonance Imaging). The study will evaluate validity, as well as test-retest reliability of digital cognitive tests, and explore associations between cognitive performance and neuroimaging outcomes.

It is expected about 36 people will participate in this research study within 12 months.

03

Conditions studied

  • PCNSL
  • Brain Tumor
  • Cognitive Dysfunction
  • IDH Mutation
  • Low-grade Glioma

Keywords

  • Primary Central Nervous System Lymphoma (PCNSL)
  • IDH-Mutant Low-Grade Glioma (LGG)
  • Brain Tumors
  • Cognitive Dysfunction
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Histopathologically confirmed newly diagnosed primary CNS diffuse large B-cell lymphoma (DLBCL) OR
  • Histopathologically confirmed IDH-M low grade glioma diagnosis in the past 12 months who have not started tumor directed therapy (if applicable).
  • Age ≥ 18 years.
  • Ability to consent to study.

Exclusion criteria

Exclusion Criteria:

  • Patients who have severe visual impairment that cannot be corrected with glasses to read regular sized print.
  • Patients who have known psychiatric or substance abuse disorders that would interfere with their cooperation in completing the requirements of the study.
05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
36 participants (estimated)

Study arms

  • Other
    Digital Cognitive Assessment

    Participants with newly diagnosed PCNSL or IDH-mutant LGG will undergo both traditional neuropsychological testing and digital cognitive assessments (TestMyBrain and Mobile Toolbox) at specified timepoints (baseline, 6 months, post-treatment or 12-14 months). Quality of life and mood questionnaires will also be administered. Brain MRI data will be collected as part of standard care. Participants will be sent a link to complete the digital cognitive tests at home. Questionnaires will also be sent via email to complete. Data will be collected from brain MRIs obtained as part of standard of care/routine surveillance. * Screening visit * Baseline visit (2- months) * Follow-Up visit (3-month) * End of Treatment 2 months after completing treatment (PCNSL only) * Final Assessment 12-14 months after baseline (LGG only). * Brain MRI (standard of care) based on participant permission There is no follow-up care as part of this research study.

    Behavioral: Digital Cognitive Assessment (TestMyBrain and Mobile Toolbox) · Behavioral: Traditional Neuropsychological Testing · Other: Quality of Life and Mood Questionnaires · Other: Brain MRI (Standard of Care)

Interventions

  • BehavioralDigital Cognitive Assessment (TestMyBrain and Mobile Toolbox)

    Participants will complete a battery of digital cognitive tests using the TestMyBrain and Mobile Toolbox platforms, assessing attention, processing speed, executive function, and memory. Assessments will be conducted in clinic and at home at multiple timepoints.

  • BehavioralTraditional Neuropsychological Testing

    Participants will complete standard paper-and-pencil neuropsychological tests, including WAIS-IV Digit Span, Brief Test of Attention, Symbol Digits Modalities Test, Trail Making Test Parts A and B, Stroop, and Hopkins Verbal Learning Test-Revised.

  • OtherQuality of Life and Mood Questionnaires

    Participants will complete the Functional Assessment of Cancer Therapy - Brain (FACT-br) and Hospital Anxiety and Depression Scale (HADS) at baseline and follow-up timepoints.

  • OtherBrain MRI (Standard of Care)

    Brain MRI data will be collected as part of routine clinical care to assess tumor response, stability, or progression, and correlated with cognitive test results.

06

What researchers measure

Primary outcomes

  1. Evaluating the Construct Validity of Digital Cognitive Tests

    To evaluate the construct validity of digital cognitive tests by comparing domain-specific composite scores derived from traditional neuropsychological and digital cognitive measures of attention, processing speed, executive functioning, and memory. Baseline traditional and digital cognitive data will be collected from PCNSL patients (before chemotherapy) and LGG patients (post-resection). Traditional tests include WAIS-IV Digit Span, Brief Test of Attention, Symbol Digit Modalities Test, Trail Making Test A/B, Stroop, and HVLT-R. Digital platforms include TestMyBrain (Digit Span, Digit Symbol Matching, Trails A/B, Reaction Time, Verbal Paired Associates) and Mobile Toolbox (Arrow Matching, Sequences, Number-Symbol Match, Shape-Color Sorting, and Associative Memory). Moderate to strong correlations between traditional and digital composite domain-specific composite scores will be interpreted as having evidence of convergent validity.

    Time frame: Baseline assessment only, conducted at study enrollment for each participant.

  2. Evaluating the Discriminant Validity of Digital Cognitive Tests with Emotional Wellbeing Measures

    To evaluate the discriminant validity of the digital cognitive tests in both cohorts ( PCNSL and LGG) by examining correlations between digital global composite indices of TestMyBrain and Mobile Toolbox tests with the emotional wellbeing subscale of the FACT-BR and the Hospital Anxiety and Depression scale. For low-grade glioma (LGG) patients, assessments will be conducted at baseline; for primary central nervous system lymphoma (PCNSL) patients, assessments will be conducted at baseline. Small magnitude correlations are expected to provide evidence of discriminant validity.

    Time frame: Baseline

  3. Assessing Test-Retest Reliability of the Digital Cognitive Tests Across Repeated Administrations and Different Environments.

    Test-retest reliability of the TestMyBrain and Mobile Toolbox cognitive tests will be evaluated in both cohorts (PCNSL and LGG) by examining correlations between baseline test scores of both groups and scores obtained at the 6-month and 12-month follow-up assessments. The baseline evaluation and 12-month evaluations will be completed in the clinic/hospital setting, and the 6-month follow-up digital cognitive tests will be completed at home. Correlations between baseline and 6-month scores will be used to evaluate the reliability of the digital cognitive measures across clinic-to-home testing environments. Correlations between baseline and 12-month scores will be used to evaluate the reliability of the digital cognitive measures across repeated assessments conducted in the same clinic/hospital environment.

    Time frame: Baseline, 6 and 12 month follow ups

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — The Dana-Farber / Harvard Cancer Center encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to: [contact information for Sponsor Investigator or designee]. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research

Supporting information: Study protocol, Statistical analysis plan

Time frame: Data can be shared no earlier than 1 year following the date of publication

Access criteria: Contact the Belfer office for Dana -Farber Innovations (BODFI) at innovations@dfci.harvard.edu

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2026 (actual). Primary completion is estimated for Jan 2028, 15 months after the start.

Of 310 non-industry interventional studies with no phase under Brain Neoplasms, half reached primary completion within 65 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 126. This study's planned 15 months is below that.

Counting every sponsor, half of 321 studies reached it within 64 months; a quarter within 35 and three quarters within 125.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 16, 2026
First posted
Jul 17, 2026
StartActual
Sep 2, 2026
Primary completionEst.
Jan 1, 2028
CompletionEst.
Jan 1, 2029
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 20, 2026
Sites
1 site added — first site in United States
Show site
  • Dana-Farber Cancer Institute · Boston, United States
Nov 20, 2026
Start date
Sep 1, 2026→Sep 2, 2026 (actual)
Nov 20, 2026
Show all 1 update
  1. Nov 20, 2026
    Not yet recruiting→Recruiting
    1 site added — first site in United States
    Show site
    • Dana-Farber Cancer Institute · Boston, United States
    Start date Sep 1, 2026→Sep 2, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07710131
Responsible party
Lakshmi Nayak, MD (Principal Investigator, Dana-Farber Cancer Institute) — Principal investigator
First posted
Jul 17, 2026
Start date
Sep 2, 2026
Primary completion
Jan 1, 2028 (estimated)
Completion
Jan 1, 2029 (estimated)
Last update
Nov 20, 2026

Study contacts

Lakshmi Nayak, MD
Contact
Lakshmi_Nayak@dfci.harvard.edu
617-632-2166
Lakshmi Nayak, MD
principal investigator · Dana-Farber Cancer Institute

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion